Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 42

Sort by

Sort Order Select

Journal Articles

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Blood (2025) 146 (Supplement 1): 3857.

https://doi.org/10.1182/blood-2025-3857

Published: 2025

Journal Articles

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Blood (2025) 146 (Supplement 1): 3848.

https://doi.org/10.1182/blood-2025-3848

Published: 2025

Journal Articles

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Blood (2025) 146 (Supplement 1): 222.

https://doi.org/10.1182/blood-2025-222

Published: 2025

Journal Articles

Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable

Blood (2018) 132 (19): 2100–2103.

https://doi.org/10.1182/blood-2018-05-848473

Published: 2018

Includes: Supplemental data

Journal Articles

CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation

Uri Rozovski, MD, David M. Harris, Ping Li, PhD, Zhiming Liu, Taghi Manshouri, Ivo Veletic, MD, Carlos Bueso-Ramos, MD PhD, Preetesh Jain, MBBS,MDDM,PhD, Srdan Verstovsek, MD PhD, Alessandra Ferrajoli, MD, Jan A. Burger, MD PhD, Prithviraj Bose, MD, Philip A Thompson, MBBS, Nitin Jain, MD, William G Wierda, MD PhD, Michael J. Keating, MD, Zeev Estrov, MD

Blood (2017) 130 (Supplement 1): 1728.

https://doi.org/10.1182/blood.V130.Suppl_1.1728.1728

Published: 2017

Journal Articles

Persistent Somatic Mutation at Remission Is Associated with Poor Survival and Higher Risk of Relapse in Patients with Acute Myeloid Leukemia

Blood (2017) 130 (Supplement 1): 2667.

https://doi.org/10.1182/blood.V130.Suppl_1.2667.2667

Published: 2017

Journal Articles

MDS and AML in Shwachman-Diamond Syndrome: Clinical Features and Outcomes

Blood (2017) 130 (Supplement 1): 1177.

https://doi.org/10.1182/blood.V130.Suppl_1.1177.1177

Published: 2017

Journal Articles

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

Blood (2017) 130 (13): 1514–1522.

https://doi.org/10.1182/blood-2017-06-788497

Published: 2017

Includes: Supplemental data

Journal Articles

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

Blood (2017) 129 (18): 2584–2587.

https://doi.org/10.1182/blood-2016-11-749903

Published: 2017

Includes: Supplemental data

Journal Articles

IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL)

Koichi Takahashi, MD, Candida Vitale, MD, Carlos Bueso-Ramos, Feng Wang, PhD, Ekaterina Kim, MS, Jianhua Zhang, Curtis Gumbs, Mark Routbort, MD PhD, Zeev Estrov, MD, Nitin Jain, MD, Guillermo Garcia-Manero, MD, Hagop M. Kantarjian, MD, Jan A. Burger, MD PhD, Alessandra Ferrajoli, MD, Michael Keating, MBBS, Andrew Futreal, PhD, William Wierda, MD PhD

Blood (2015) 126 (23): 4136.

https://doi.org/10.1182/blood.V126.23.4136.4136

Published: 2015

Journal Articles

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)

Preetesh Jain, MBBS,MDDM,PhD, Keyur P. Patel, MD PhD, Andrew Futreal, PhD, Curtis Gumbs, Shimin Hu, PhD MD, Carlos Bueso Ramos, MD, Michael Wang, MD, Jorge Romaguera, Luis E. Fayad, MD, Robert Z. Orlowski, PhD, MD, Jeffrey Medeiros, Nathan Fowler, MD

Blood (2015) 126 (23): 2700.

https://doi.org/10.1182/blood.V126.23.2700.2700

Published: 2015

Journal Articles

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms

Blood (2014) 123 (17): 2645–2651.

https://doi.org/10.1182/blood-2014-02-553800

Published: 2014

Includes: Supplemental data

Journal Articles

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Koichi Takahashi, Naveen Pemmaraju, Paolo Strati, Graciela Nogueras-Gonzalez, Jing Ning, Carlos Bueso-Ramos, Rajyalakshmi Luthra, Sherry Pierce, Jorge Cortes, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2013) 122 (16): 2807–2811.

https://doi.org/10.1182/blood-2013-03-491399

Published: 2013

Includes: Supplemental data

Journal Articles

Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment

V. Lokesh Battula, Ye Chen, Maria da Graca Cabreira, Vivian Ruvolo, Zhiqiang Wang, Wencai Ma, Sergej Konoplev, Elizabeth Shpall, Karen Lyons, Dirk Strunk, Carlos Bueso-Ramos, Richard Eric Davis, Marina Konopleva, Michael Andreeff

Blood (2013) 122 (3): 357–366.

https://doi.org/10.1182/blood-2012-06-437988

Published: 2013

Includes: Supplemental data

Journal Articles

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

Kiran Naqvi, Elias Jabbour, Carlos Bueso-Ramos, Sherry Pierce, Gautam Borthakur, Zeev Estrov, Farhad Ravandi, Stefan Faderl, Hagop Kantarjian, Guillermo Garcia-Manero

Blood (2011) 118 (17): 4690–4693.

https://doi.org/10.1182/blood-2011-03-342642

Published: 2011

Journal Articles

Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB–inducing kinase while activating both canonical and alternative nuclear factor-κB pathways

Lan V. Pham, Lingchen Fu, Archito T. Tamayo, Carlos Bueso-Ramos, Elias Drakos, Francisco Vega, L. Jeffrey Medeiros, Richard J. Ford

Blood (2011) 117 (1): 200–210.

https://doi.org/10.1182/blood-2010-06-290437

Published: 2011

Includes: Supplemental data

Journal Articles

An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas

Lan V. Pham, Archito T. Tamayo, Changping Li, Carlos Bueso-Ramos, Richard J. Ford

Blood (2010) 116 (19): 3899–3906.

https://doi.org/10.1182/blood-2009-12-257378

Published: 2010

Journal Articles

APcK 110, a novel Inhibitor of Kit, Extends Survival of NOD-SCID Mice in An AML Xenograft Model.

Stefan Faderl, MD, Carlos Bueso-Ramos, MD, PhD, Zhiming Liu, Ashutosh Pal, William Bornmann, PhD, David Harris, Inbal Hazan-Halevy, PhD, Hagop M. Kantarjian, MD, Zeev Estrov, MD

Blood (2009) 114 (22): 1045.

https://doi.org/10.1182/blood.V114.22.1045.1045

Published: 2009

Journal Articles

TET2 and ASXL1 Mutations in Leukemic Transformation of Chronic Myeloproliferative Neoplasms.

Omar Abdel-Wahab, Taghi Manshouri, Jay Patel, Kelly Harris, Jin Juan Yao, MD, PhD, Cyrus V. Hedvat, MD, PhD, Adriana Heguy, Carlos Bueso-Ramos, Hagop M. Kantarjian, MD, Ross L. Levine, MD, Srdan Verstovsek, MD, PhD

Blood (2009) 114 (22): 2894.

https://doi.org/10.1182/blood.V114.22.2894.2894

Published: 2009

Journal Articles

Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3.

Xavier C. Badoux, MBBS, Carlos Bueso Ramos, MD, PhD, David Harris, B.S., Ping Li, Ph.D., Zhiming Liu, B.S., Jan Burger, M.D., Susan O'Brien, MD, Alessandra Ferrajoli, MD., Michael Keating, MD, Zeev Estrov, MD

Blood (2009) 114 (22): 1242.

https://doi.org/10.1182/blood.V114.22.1242.1242

Published: 2009

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

RUNX1 mutations define a high-risk biological subset of chronic myelomonocytic leukemia and cooperate with ASXL1 mutations to drive leukemic transformation

Multimodal assessment of chronic myelomonocytic leukemia with extramedullary involvement reveals RAS pathway activation, adverse outcomes and epithelial-mesenchymal transition

Phenotypic heterogeneity and remodeling drive resistance to venetoclax treatment in acute myeloid leukemia

Mutational landscape of myelodysplastic/myeloproliferative neoplasm–unclassifiable

CLL Cell-Derived Exosomes Promote Bone Marrow Fibrosis and Inhibit Normal Hematopoietic Colony Proliferation

Persistent Somatic Mutation at Remission Is Associated with Poor Survival and Higher Risk of Relapse in Patients with Acute Myeloid Leukemia

MDS and AML in Shwachman-Diamond Syndrome: Clinical Features and Outcomes

Randomized phase 2 study of low-dose decitabine vs low-dose azacitidine in lower-risk MDS and MDS/MPN

More than 1 TP53 abnormality is a dominant characteristic of pure erythroid leukemia

IKZF3 p.L162R Is a Recurrent Hotspot Mutation in Chronic Lymphocytic Leukemia (CLL)

Clinico-Pathological Characteristics, Treatments and Outcomes of Patients with Dendritic Cell Sarcoma (DS)

Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms

Clinical characteristics and outcomes of therapy-related chronic myelomonocytic leukemia

Connective tissue growth factor regulates adipocyte differentiation of mesenchymal stromal cells and facilitates leukemia bone marrow engraftment

Implications of discrepancy in morphologic diagnosis of myelodysplastic syndrome between referral and tertiary care centers

Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-κB–inducing kinase while activating both canonical and alternative nuclear factor-κB pathways

An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas

APcK 110, a novel Inhibitor of Kit, Extends Survival of NOD-SCID Mice in An AML Xenograft Model.

TET2 and ASXL1 Mutations in Leukemic Transformation of Chronic Myeloproliferative Neoplasms.

Cross-Talk Between CLL Cells and Endothelial Cells in the Bone Marrow Microenvironment: Role of Signal Transducer and Activator of Transcription (Stat)-3.

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only